A Randomized Trial of a Low Dose Rasagiline and Pramipexole Combination (P2B001) in Early Parkinson’s Disease
April 3, 2017
C. Warren Olanow MD, Karl Kieburtz MD, Mika Leinonen MSc, Lawrence Elmer MD, Nir Giladi MD, Robert A. Hauser MD, Olga S. Klepiskaya MD, David
Pharma Two B Announces Positive Results in its Phase IIb Pivotal Clinical Study of P2B001 for the Treatment of Early Stage Parkinson’s Disease
June 30, 2015
Rehovoth, Israel, June 30, 2015 — Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the
Pharma Two B taking ‘synergistic’ approach in pursuit of 505(b)(2) approval
April 22, 2011
Published in Scrip Magazine by Donna Young, April 22nd 2011 Israeli start-up Pharma Two B has taken the concept of synergism seriously, from the eclectic